Insights Into Metastatic Castration-Resistant Prostate Cancer Southeast

Perspectives on current treatment practices regarding genetic testing in metastatic castration-resistant prostate cancer (mCRPC), first-line treatment of mCRPC, and management of progressive and/or symptomatic mCRPC

Southeast – December 22, 2020
Purchase Report

Faculty Chair

Neal Shore, MD, FACS

Atlantic Urology Clinics, SC, US

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of mCRPC was held on December 22, 2020
  • Disease state and data presentations were developed in conjunction with Neal Shore, MD, FACS, from the Atlantic Urology Clinics
  • Insights into genetic testing methods and therapies were obtained, with a particular focus on olaparib, rucaparib, genetic testing (somatic/germline), BRCA, HRR, and PALB2 mutations

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • Attendees of the roundtable represented community oncologists from Georgia, Tennessee, Florida, and South Carolina

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.